Unknown

Dataset Information

0

A20-binding inhibitor of NF-?B (ABIN1) controls Toll-like receptor-mediated CCAAT/enhancer-binding protein ? activation and protects from inflammatory disease.


ABSTRACT: Toll-like receptors (TLRs) are expressed on innate immune cells and trigger inflammation upon detection of pathogens and host tissue injury. TLR-mediated proinflammatory-signaling pathways are counteracted by partially characterized anti-inflammatory mechanisms that prevent exaggerated inflammation and host tissue damage as manifested in inflammatory diseases. We biochemically identified a component of TLR-signaling pathways, A20-binding inhibitor of NF-?B (ABIN1), which recently has been linked by genome-wide association studies to the inflammatory diseases systemic lupus erythematosus and psoriasis. We generated ABIN1-deficient mice to study the function of ABIN1 in vivo and during TLR activation. Here we show that ABIN1-deficient mice develop a progressive, lupus-like inflammatory disease characterized by expansion of myeloid cells, leukocyte infiltrations in different parenchymatous organs, activated T and B lymphocytes, elevated serum Ig levels, and the appearance of autoreactive antibodies. Kidneys develop glomerulonephritis and proteinuria, reflecting tissue injury. Surprisingly, ABIN1-deficient macrophages exhibit normal regulation of major proinflammatory signaling pathways and mediators but show selective deregulation of the transcription factor CCAAT/enhancer binding protein ? (C/EBP?) and its target genes, such as colony-stimulating factor 3 (Csf3), nitric oxide synthase, inducible (Nos2), and S100 calcium-binding protein A8 (S100a8). Their gene products, which are intimately linked to innate immune cell expansion (granulocyte colony-stimulating factor), cytotoxicity (inducible nitric oxide synthase), and host factor-derived inflammation (S100A8), may explain, at least in part, the inflammatory phenotype observed. Together, our data reveal ABIN1 as an essential anti-inflammatory component of TLR-signaling pathways that controls C/EBP? activity.

SUBMITTER: Zhou J 

PROVIDER: S-EPMC3207663 | biostudies-literature | 2011 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

A20-binding inhibitor of NF-κB (ABIN1) controls Toll-like receptor-mediated CCAAT/enhancer-binding protein β activation and protects from inflammatory disease.

Zhou Jingran J   Wu Ruiqiong R   High Anthony A AA   Slaughter Clive A CA   Finkelstein David D   Rehg Jerold E JE   Redecke Vanessa V   Häcker Hans H  

Proceedings of the National Academy of Sciences of the United States of America 20111019 44


Toll-like receptors (TLRs) are expressed on innate immune cells and trigger inflammation upon detection of pathogens and host tissue injury. TLR-mediated proinflammatory-signaling pathways are counteracted by partially characterized anti-inflammatory mechanisms that prevent exaggerated inflammation and host tissue damage as manifested in inflammatory diseases. We biochemically identified a component of TLR-signaling pathways, A20-binding inhibitor of NF-κB (ABIN1), which recently has been linked  ...[more]

Similar Datasets

| S-EPMC3904707 | biostudies-literature
| S-EPMC6219730 | biostudies-literature
| S-EPMC3532050 | biostudies-other
| S-EPMC4849162 | biostudies-literature
| S-EPMC4815975 | biostudies-other
| S-EPMC3460927 | biostudies-literature
| S-EPMC4196981 | biostudies-literature
| S-EPMC6226455 | biostudies-literature
| S-EPMC9252280 | biostudies-literature
| S-EPMC9810737 | biostudies-literature